• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
ZHOU Anwei,JU Caoyun,ZHANG Can.Drug delivery systems of tumor necrosis factor-related apoptosis-inducing ligand in tumor therapy[J].Journal Of Pharmaceutical Research,2018,37(9):523-527[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 3129times   Download 3070次 QR Code for this article
Scan with your phone!
药物载体用于递送肿瘤坏死因子相关凋亡诱导配体的研究进展
周安维,鞠曹云,张灿
Font:Larger+|Default|Smaller-
(中国药科大学新药研究中心,高端药物制剂与材料研究中心,南京 210009)
摘要:
肿瘤坏死因子相关凋亡诱导配体(Tumor necrosis factor-related apoptosis-inducing ligand,TRAIL)是肿瘤坏死因子家族的成员之一,可与肿瘤细胞膜表面过度表达的死亡受体4或5结合,特异性诱导肿瘤细胞凋亡,且对正常细胞无明显影响,因此被认为是临床最有发展前景的蛋白药物之一。然而,由于肿瘤坏死因子相关凋亡诱导配体存在体内稳定性差和生物利用度低等缺点,限制了其在临床中的应用。运用药物载体对肿瘤坏死因子相关凋亡诱导配体进行递送,成为目前解决此弊端的有效策略。本综述简要介绍了近年来药物载体在肿瘤坏死因子相关凋亡诱导配体递送方面的研究进展。
关键词:  肿瘤坏死因子相关凋亡诱导配体  药物递送载体  肿瘤治疗
DOI:10.13506/j.cnki.jpr.2018.09.009
基金项目:国家自然科学基金资助项目(No. 81773664、81503003、81473153)
Drug delivery systems of tumor necrosis factor-related apoptosis-inducing ligand in tumor therapy
ZHOU Anwei,JU Caoyun,ZHANG Can
(Center of Advanced Pharmaceuticals and Biomaterials,Center of New Drug Discovery,China Pharmaceutical University,Nanjing 210009,China)
Abstract:
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of tumor necrosis factor family, which specifically binds to death receptor 4 or death receptor 5 overexpressed on the cell membrane surface of tumor cells, thus inducing cell apoptosis while sparing normal cells.Therefore,it has become one of the promising protein drug in tumor therapy.However,TRAIL exihits poor stability and bioavailability in vivo,which strongly limits the clinical application. In order to potentiate beneficial properties of TRAIL,and avoid these disadvantages,drug carries were discovered,which emerging as a new strategy for TRAIL delivery.This review provided a brief overview of the recent advances in drug delivery of TRAIL.
Key words:  Tumor necrosis factor-related apoptosis-inducing ligand  Drug delivery carriers  Tumor therapy
Today's Visits:511    Total Visits:2383242
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.